"Nuclear medicine and molecular imaging organization singles out Dr. Adrien Holzgreve as a notable professional to keep an eye on"
Cracking the Code on Prostate Cancer: UCLA's Rising Star, Dr. Adrien Holzgreve, Makes a Mark
Dr. Adrien Holzgreve, a whizz kid in the realm of nuclear medicine and molecular imaging, has just scored a big one. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has shone the spotlight on him as an up-and-coming leader in this field, earning him a spot in their coveted "Ones to Watch" program.
This puts Dr. Holzgreve in an exclusive club of future shapers in nuclear medicine and molecular imaging, paving the way for precision medicine.
Working under the watchful eye of Dr. Jeremie Calais, the director of the Ahmanson Translational Theranostics Division’s clinical research program and a big cheese at the our website Jonsson Comprehensive Cancer Center, Dr. Holzgreve is delving deep into the potential of state-of-the-art imaging technologies like the PSMA-PET (a fancy PET scan that homes in on prostate-specific membrane antigen) and treatments such as PSMA radioligand therapy to manage patients battling prostate cancer.
But that's not all. Most recently, Dr. Holzgreve's team has unearthed a bombshell. They discovered that almost half of high-risk prostate cancer patients, who were initially thought to be in the nonmetastatic, hormone-sensitive stage, had in fact missed metastatic spread on conventional imaging. This breakthrough has major ramifications for clinical trial construction and treatment planning, reinforcing the necessity of incorporating molecular imaging into the standard of care for more precise guidance of personalized treatments.
"It's a true honor to be recognized by the SNMMI," Dr. Holzgreve shared. "This acknowledgement is testament to the strength of our squad at UCLA and our collective drive to push the envelope of how we perceive, diagnose, and treat cancer with advanced theranostic concepts."
In essence, this kid's the real deal. Stay tuned for more groundbreaking discoveries from this dynamic duo at UCLA!
- Dr. Adrien Holzgreve, a prostate cancer researcher at UCLA, has been recognized by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for his potential in nuclear medicine and molecular imaging.
- Working under Dr. Jeremie Calais at Jonsson Comprehensive Cancer Center, Dr. Holzgreve is investigating the use of molecular imaging technologies like PSMA-PET and treatments such as PSMA radioligand therapy for managing prostate cancer.
- Recenty, Dr. Holzgreve's team found that over half of high-risk prostate cancer patients, who were initially thought to be in the nonmetastatic, hormone-sensitive stage, had in fact missed metastatic spread on conventional imaging.
- This discovery has significant implications for clinical trial construction and treatment planning, emphasizing the importance of incorporating molecular imaging into the standard of care for more precise guidance of personalized treatments.
- In the realm of health-and-wellness, medical-conditions like cancer can be better managed through advances in science, therapies-and-treatments, and precision medicine, as demonstrated by the work of Dr. Adrien Holzgreve and his team at UCLA.
